skip to main | skip to sidebar

Afrezza

AFREZZA™ is a novel, ultra rapid acting mealtime insulin therapy by Mannkind Corporation. Visit Mannkind's official website www.mannkindcorp.com for more information;

  • Site Map
  • Home
  • Afrezza
  • Mannkind
  • Analysts
  • CEO
  • Stock
  • Physicians
  • Patients
  • News
  • Report

Tuesday, December 29, 2009

Seeking alpha MNKD Transcripts

Seeking alpha MNKD Transcripts
Email ThisBlogThis!Share to TwitterShare to Facebook
Labels: Transcripts

Newer Post Older Post Home

Search This Blog

Loading...

Interviews with management

  • Interview with Alfred E. Mann - June-2010
  • Al Mann speech at Johns Hopkins - 2010 (new)
  • Al Mann speech at OCR - 2010 (new)
  • Fox news video on inhaled insulin
  • Pete Richardson - Clip syndicate video
  • MannKind's CFO Pfeffer Upbeat on Afresa's Future
  • Interview with Dr Andrea Leone Bay
  • Hakan interview - may 26-2010

MNKD Quick quote

Upcoming events

Afrezza

Completion of pt enrollment in Studies 171 and 174 - 2Q12
Completion of Studies 171 and 174 - YE12
Results of Studies 171 and 174 - Late 2012/1Q13
Re-submission to FDA - 1H13
Potential 3rd PDUFA - 4Q13

Subscribe To Afrezza blog

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ►  2013 (7)
    • ►  May (3)
    • ►  March (3)
    • ►  January (1)
  • ►  2012 (24)
    • ►  November (1)
    • ►  August (1)
    • ►  July (1)
    • ►  May (1)
    • ►  April (1)
    • ►  March (6)
    • ►  February (6)
    • ►  January (7)
  • ►  2011 (34)
    • ►  November (2)
    • ►  October (2)
    • ►  August (5)
    • ►  July (1)
    • ►  June (3)
    • ►  May (5)
    • ►  March (4)
    • ►  February (2)
    • ►  January (10)
  • ►  2010 (124)
    • ►  December (19)
    • ►  November (11)
    • ►  October (12)
    • ►  September (9)
    • ►  August (16)
    • ►  July (8)
    • ►  June (14)
    • ►  May (21)
    • ►  April (3)
    • ►  March (6)
    • ►  February (5)
  • ▼  2009 (9)
    • ▼  December (9)
      • MannKind's CFO Pfeffer Upbeat on Afresa's Future: ...
      • Fate of Mankind
      • Seeking alpha MNKD Transcripts
      • *** Must read/see interviews ****
      • Inhaled insulin comparable to insulin aspart for T...
      • Abstracts 1
      • ADA 2009: New Inhaled Insulin Has Rapid Onset of A...
      • The case for Mannkind
      • Why is Afrezza better?

Labels

Wells Fargo (13) Rodman (10) HbA1C (8) afrezza (8) Bank of America (7) Al Mann (6) FDA (5) Mannkind (5) Hapoalim (4) Oppenheimer (4) Griffin (3) JP Morgan (3) Leerink (3) Renshaw (3) Research analyst (3) TI (3) CRT (2) Comparison of Exubera and Afresa (2) Diabetologists (2) Early intervention (2) JMP (2) Joshua Schimmer (2) Piper Jaffray (2) Technosphere (2) first phase insulin release (2) hypos (2) titration (2) Approval (1) Baird (1) Comments (1) Cramer (1) Guest contributor (1) Heinemann (1) Morgan Stanley (1) PPG (1) Pulmonary Delivery (1) Real users (1) Shorts (1) Transcripts (1) Valuation (1) eAG (1) earnings conference call summary (1) interview (1)

Links I like

  • KLLJ blog
  • Robert S. Horn Medbio

Yahoo !

Google Mannkind feed

Loading...
 

Mannkind's products

Mannkind's products